Janet E. McElhaney

Janet E. McElhaney

Auto-generated profile, based on publicly available information

Janet E. McElhaney

Health Sciences North Research Institute, Sudbury, ON, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2019 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
LOLidia Oostvogels
Lidia Oostvogels
THThomas C. Heineman
Thomas C. Heineman
RJRobert W. Johnson
Robert W. Johnson
MLMyron J. Levin
Myron J. Levin
JMJanet E. McElhaney
Janet E. McElhaney
Anthony L. CunninghamAnthony L. Cunningham
Anthony L. Cunningham
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to receive 2 doses of RZV or placebo 2 months apart. Vaccine efficacy and safety were evaluated post-hoc in the pooled (ZOE-50/70) population according to the number and type of selected medical conditions present at enrollment. At enrollment, 82.3% of RZV and 82.7% of placebo recipients reported ≥1 of the 15 selected medical conditions. Efficacy against HZ ranged from 84.5% (95% Confidence Interval [CI]: 46.4–97.1) in participants with respiratory disorders to 97.0% (95%CI: 82.3–99.9) in those with coronary heart disease. Moreover, efficacy remained >90% irrespective of the number of selected medical conditions reported by a participant. As indicated by the similarity of the point estimates, this post-hoc analysis suggests that RZV efficacy remains high in all selected medical conditions, as well as with increasing number of medical conditions. No safety concern was identified by the type or number of medical conditions present at enrollment.

26 May 2022 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
EPEmilie Picard
Emilie Picard
SASarah Armstrong
Sarah Armstrong
MAMelissa K. Andrew
Melissa K. Andrew
LHLaura Haynes
Laura Haynes
MLMark Loeb
Mark Loeb
CVChris Verschoor
Chris Verschoor
Background: With increasing age, overall health declines while systemic levels of inflammatory mediators tend to increase. Although the underlying mechanisms are poorly understood, there is a wealth of data suggesting that this so-called “inflammaging” contributes to the risk of adverse outcomes in older adults. We sought to determine whether markers of systemic inflammation were associated with antibody responses to the seasonal influenza vaccine. Results: Over four seasons, hemagglutination inhibition antibody titres and ex vivo bulk peripheral blood mononuclear cell (PBMC) responses to live influenza viruses assessed via interferon (IFN)-γ/interleukin (IL)-10 production, were measured pre- and 4-weeks post-vaccination in young adults (n = 79) and older adults randomized to standard- or high-dose inactivated vaccine (n = 612). Circulating tumour necrosis factor (TNF), interleukin (IL)-6 and C-reactive protein (CRP) were also measured pre-vaccination. Post-vaccination antibody titres were significantly associated with systemic inflammatory levels; specifically, IL-6 was positively associated with A/H3N2 titres in young adults (Cohen’s d = 0.36), and in older high-dose, but not standard-dose recipients, all systemic inflammatory mediators were positively associated with A/H1N1, A/H3N2 and B titres (d = 0.10–0.45). We further show that the frequency of ILT2(+)CD57(+) CD56-Dim natural killer (NK)-cells was positively associated with both plasma IL-6 and post-vaccination A/H3N2 titres in a follow-up cohort of older high-dose recipients (n = 63). Pathway analysis suggested that ILT2(+)CD57(+) Dim NK-cells mediated 40% of the association between IL-6 and A/H3N2 titres, which may be related to underlying participant frailty. Conclusions: In summary, our data suggest a complex relationship amongst influenza vaccine responses, systemic inflammation and NK-cell phenotype in older adults, which depends heavily on age, vaccine dose and possibly overall health status. While our results suggest that “inflammaging” may increase vaccine immunogenicity in older adults, it is yet to be determined whether this enhancement contributes to improved protection against influenza disease.

1 February 2020 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JLJason J. LeBlanc
Jason J. LeBlanc
MEM. ElSherif
M. ElSherif
SMS. Mulpuru
S. Mulpuru
MWM. Warhuus
M. Warhuus
AAA. Ambrose
A. Ambrose
SMS. A. McNeil
S. A. McNeil
Background. The Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN SOS) has been performing active influenza surveillance since 2009 (ClinicalTrials.gov identifier: NCT01517191). Influenza A and B viruses are identified and characterized using real-time reverse-transcriptase polymerase chain reaction (RT-PCR), and multiplex testing has been performed on a subset of patients to identify other respiratory virus aetiologies. Since both methods can identify influenza A and B, a direct comparison was performed. Methods. Validated real-time RT-PCRs from the World Health Organization (WHO) to identify influenza A and B viruses, characterize influenza A viruses into the H1N1 or H3N2 subtypes and describe influenza B viruses belonging to the Yamagata or Victoria lineages. In a subset of patients, the Seeplex RV15 One-Step ACE Detection assay (RV15) kit was also used for the detection of other respiratory viruses. Results. In total, 1111 nasopharyngeal swabs were tested by RV15 and real-time RT-PCRs for influenza A and B identification and characterization. For influenza A, RV15 showed 98.0 % sensitivity, 100 % specificity and 99.7 % accuracy. The performance characteristics of RV15 were similar for influenza A subtypes H1N1 and H3N2. For influenza B, RV15 had 99.2 % sensitivity, 100 % specificity and 99.8 % accuracy, with similar assay performance being shown for both the Yamagata and Victoria lineages. Conclusions. Overall, the detection of circulating subtypes of influenza A and lineages of influenza B by RV15 was similar to detection by real-time RT-PCR. Multiplex testing with RV15 allows for a more comprehensive respiratory virus surveillance in hospitalized adults, without significantly compromising the reliability of influenza A or B virus detection.

1 September 2002 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
JMJanet E. McElhaney
Janet E. McElhaney
CURRENT influenza vaccines are 50% to 60% effective for preventing serious illness in older people but may be limited in persons with poor health, particularly in the institutional setting (1). Poor nutritional status occurs commonly in older persons (2)(3). Improving nutritional status may be one strategy for enhancing the response to influenza vaccination in older adults. Thus, in mice, Han and colleagues (4) showed that a vitamin E supplement would reduce influenza viral titers during an infection and decrease the anorexia and weight loss produced by influenza. Pollett and colleagues (5) showed that protein-deprived mice had reduced IgM antibody response to intranasal influenza infection. Chandra and Puri (6) found that, in humans, nutritional support improved the antibody response to influenza virus. In contrast, Pozzetto and colleagues (7) reported no relationship of protein status to postvaccinal antibody response to influenza viruses in older humans.

1 April 2018 in EBioMedicine
Verified
Journal Article
Open access
Graham PawelecGraham Pawelec
Graham Pawelec
JMJanet McElhaney
Janet McElhaney